About jazz pharmaceuticals - JAZZ
Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
JAZZ At a Glance
Jazz Pharmaceuticals Plc
Waterloo Exchange
Dublin, Dublin 4
| Phone | 353-1-634-7800 | Revenue | 4.27B | |
| Industry | Pharmaceuticals: Major | Net Income | -356,148,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 4.882% | |
| Fiscal Year-end | 12 / 2026 | Employees | 2,890 | |
| View SEC Filings |
JAZZ Valuation
| P/E Current | 16.59 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 2.429 |
| Price to Book Ratio | 2.418 |
| Price to Cash Flow Ratio | 7.65 |
| Enterprise Value to EBITDA | 9.225 |
| Enterprise Value to Sales | 3.129 |
| Total Debt to Enterprise Value | 0.406 |
JAZZ Efficiency
| Revenue/Employee | 1,476,673.356 |
| Income Per Employee | -123,234.602 |
| Receivables Turnover | 5.137 |
| Total Asset Turnover | 0.361 |
JAZZ Liquidity
| Current Ratio | 1.858 |
| Quick Ratio | 1.672 |
| Cash Ratio | 1.089 |
JAZZ Profitability
| Gross Margin | 72.866 |
| Operating Margin | 17.601 |
| Pretax Margin | -14.712 |
| Net Margin | -8.345 |
| Return on Assets | -3.009 |
| Return on Equity | -8.467 |
| Return on Total Capital | -3.654 |
| Return on Invested Capital | -3.766 |
JAZZ Capital Structure
| Total Debt to Total Equity | 125.673 |
| Total Debt to Total Capital | 55.688 |
| Total Debt to Total Assets | 46.549 |
| Long-Term Debt to Equity | 101.484 |
| Long-Term Debt to Total Capital | 44.97 |